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Abstract.  We have studied the ability of the neu tyro- 
sine kinase to induce a  signal  for the activation of cell 
growth-regulated genes.  Serum-starved NIH 3T3 cells 
expressing an epidermal growth factor receptor (EGF- 
R)/neu construct encoding a hybrid receptor protein 
were stimulated with EGF and the activation of the 
neu tyrosine kinase and stimulation of growth factor 
inducible genes were followed at the mRNA, protein, 
and activity levels, and compared to the corresponding 
responses in the neu proto-oncogene and oncogene ex- 
pressing cells.  Induction of the expression ofjun 
mRNAs was an immediate early effect of EGF stimu- 
lation,  followed by a marked increase in the biosynthe- 
sis of the fos/jun transcription  factor complex and an 
increased transcription  factor activity as measured by a 
recombinant transcription  unit using chloramphenicol 
acetyltransferase assays. In distinction,  elevated AP- 
1/PEA-1 activity in the absence of a  significant in- 
crease in jun and fos expression was characteristic  of 
the neu oncogene-expressing cells. The glucose trans- 
porter mRNA increased at 2 h of EGF stimulation and 
was associated with enhanced glucose transport of the 
EGF-treated cells. An increase of ornithine decarboxy- 
lase (ODC) mRNA and activity followed these 
changes.  In contrast,  serum-starved,  EGF-treated neu 
proto-oncogene- and oncogene-expressing cells showed 
constitutively low and high glucose transporter and 
ODC activities,  respectively. These findings demon- 
strate that the chimeric  EGF-R/neu receptor is capable 
of activating the expression of both immediate early 
genes and biochemical activities associated with cell 
growth stimulation. 
cells are  rendered  capable of traversing 
e cell cycle by a cascade of events initiated  by the 
binding of growth factors to their receptors at the cell 
surface and resulting  in the activation  of genes and 
biochemical activities expressed during the Gt and S phases 
of the cell cycle (Heldin and Westermark,  1984; Lau and Na- 
thans,  1987; Almendral  et al.,  1988). However, growth fac- 
tors differ in their  effects on different  cells.  They can be 
classified into at least two categories,  called the competence 
and  progression  factors,  depending  on  whether  they  are 
sufficient for the transfer of stimulated cells from a quiescent 
state  (Go) back to the cell  cycle or whether they are  re- 
quired later, during cell progression into the S phase (Har- 
rington and Pledger,  1987). This specificity of growth factor 
action is determined by the specific growth factor receptors, 
their effector functions, signal transduction  mechanisms,  and 
substrates,  which are reflected at the genomic level in the ac- 
tivation  of cell- and growth factor-specific  gene responses. 
Oncogenes can deregulate signal transduction  mechanisms 
and growth factor inducible genes at various levels and pre- 
vent cells from entering  a quiescent stage. 
The biochemical mechanisms of signal transduction  used 
by many growth factor receptors remain uncharacterized  in 
the absence of known ligands for several growth factor recep- 
tor tyrosine kinases encoded by genes that have been cloned 
recently. Thus,  the protein product of the neu oncogene has 
been assumed to function as a tyrosine kinase growth factor 
receptor because of its close homology and immunochemi- 
cal  similarity  with  the  epidermal  growth  factor  receptor 
(EGF-R) t (Schechter et al.,  1984; Bargmann et al.,  1986a). 
Consistent with this idea, the rat neu protein,  activated by a 
point mutation in the transmembrane domain of the putative 
receptor,  has a  tyrosine kinase activity (Bargmann  et al., 
1986b) as does its human homologue, the HER2/erbB2 pro- 
tein,  when overexpressed in NIH 3T3 cells (Hudziak et al., 
1987). It is not known, however, how the function of the neu 
oncoprotein differs from its normal counterpart and what is 
the mechanism of cell transformation  by the mutant protein. 
We have undertaken a study of the function of the neu tyro- 
sine kinase by expressing  a chimeric  EGF-R/neu protein  in 
NIH 3T3 cells and analyzing  its tyrosine kinase activity and 
effects in ceils stimulated by EGF (Lehviislaiho et al., 1989). 
This study has indicated  that the ligand-activated  neu tyro- 
sine kinase is capable of inducing DNA synthesis in resting 
I. Abbreviations used in this paper: CAT, chlommphenicol acetyltransfer- 
ase;  CHX,  cycloheximide;  2-DOG,  2-deoxyglucose;  EGE  epidermal 
growth factor;  EGF-R, EGF receptor; GT, glucose transporter; ODC,  or- 
nithine decarboxylase;  TRE,  12-O-tetradecanoyl-phorbol-13-acetate-re- 
sponsive element. 
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receptor overexpression (Lehtola et al.,  1989; Lehv/islaiho 
et al.,  1989). We have now initiated a more detailed analysis 
of the effects of the ligand-activated neu tyrosine kinase on 
several growth-regulated genes and biochemical functions. 
Using our chimeric receptor system, we could also compare 
the status of expression of these genes and activities in the 
neu proto-oncogene- and oncogene-expressing cells. 
Materials and Methods 
Cells and Transfections 
The NIH 3T3 cells expressing less than 8  x  103 EGF receptors/cell were 
transfected with the pSV2EGF-R/neu vector (Lehv~islaiho et al.,  1989) ac- 
cording to the calcium phosphate precipitation technique described by Gra- 
ham and van der Eb (1973).  The following cell clones expressing various 
levels of the chimeric EGF-Rlneu protein were obtained: NEN7 (2  x  106 
receptors/cell), NENI6 (4  x  105 receptors/cell), NEN37 (4  x  105 recep- 
tors/ceil), and NEN49 (5  ×  105 receptors/cell). The NN cells expressing 
only the neomycin resistance marker gene were used as control cells in most 
experiments, since all transfections included the marker plasmid pSV2neo 
(No. 37149; American Type Culture Collection, Rockville, MD). We also 
produced various neu-transfected cell clones for control experiments: the 
N6 cells express the neu proto-oncogene (LTRneuN) while the NT8, NT11 
and NT12 cells express the neu oncogene differing from the proto-oncogene 
by a single point mutation in the transmembrane domain (SV2neuNT; Barg- 
mann et al.,  1986/7). The C125  cells are NIH 31"3 derivatives expressing 
'~4  ×  105 human EGF-R/cell (Velu et al.,  1987). 
The cells were grown at 37°C in DME supplemented with 10% FCS. FOr 
selection of the transfectants, the (3418 antibiotic was added at a concentra- 
tion of 200-400/~g/ml. Before each growth factor stimulation experiment, 
the cells were washed with serum-free medium and incubated in 0.5% FCS 
for 16-48 h. The cells were routinely checked for mycoplasma contamina- 
tion using fluorochrome 33 258 (Hoechst; Calbiochem-Behring Corp., San 
Diego, CA) (Russell et al.,  1975),  with negative results. 
Reagents 
Receptor-grade EGF from mouse submaxillary glands was obtained from 
Collaborative Research, Inc. (Waltham, MA) 125I-labeled mouse EGF (100 
/~Ci//~g), ),[32PlATP (>5,000 Ci/mmol), 135Slmethionine (1,000 Ci/mmol), 
2-deoxy-D[1-3Hlglucose  (17 Ci/mmol), L-[1J4C]ornithine (59 mCi/mmol), 
and  o-threo-[dichloroacetyl-l-laC]chloramphenicol (54  mCi/mmol) were 
from Amersham Corp. (Arlington Heights, IL); protein A-Sepharose, ace- 
tyl coenzyme A, and chloramphenicol acetyltransferase (Escherichia coli) 
(Pharmacia Fine Chemicals, Uppsala, Sweden), D luciferin from Enzyma- 
tix Ltd. (Cambridge, UK), and cell culture reagents including the neomy- 
cin analogue geneticin (G418  sulphate) from Gibco Laboratories (Grand 
Island, NY). 
Molecular Clones 
The proto-oncogene neu cDNA and SV40 polyadenylation site from plas- 
mid pSV2neuN (Bargmann et al.,  1986b)  and Moloney murine leukemia 
virus LTR from plasmid pMP-1 (Schwab et al., 1985) were joined together 
in pSP72 (Promega Biotec, Madison, WI)) cloning vector to yield the ex- 
pression vector pLTRneuN. 
The following cDNA clones were used as molecular probes: pODC  16 
(mouse ornithine decarboxylase; J~inne et al., 1984),  pGT4-12  (rat glucose 
transporter;  Birnbaum  et  al.,  1986).  p465.20  (junB;  Lau  and  Nathans, 
1987),  ph-cJ-1 (c-jun; Angel et al., 1988a), pRGAPDH-13 (rat glyceralde- 
hyde phosphate dehydrogenase; Fort et al.,  1985).  Nick translations of 
DNA were carried out according to the manufacturer's instructions (Amer- 
sham Corp.). Plasmid pBLCAT2 containing the herpes virus thymidine ki- 
nase promoter in front of the chloramphenicol acetyltransferase coding se- 
quence  (CAT)  and  plasmid p5xTREtkCAT  where a  synthetic,  fivefold 
human metallothionein IIA TPA-responsive DNA element (TRE:  GTG- 
ACTCAG) is inserted in front of the thymidine kinase promoter in pBLCAT2 
were kind gifts from Dr. Peter Angel (Angel et al., 1987).  Plasmid pRSVL 
contains the full-length, intronless luciferase gene isolated from the firefly 
Photinus pyralis, placed under control of the Rous Sarcoma virus LTR (de 
Wet et al.,  1987).  This plasmid was kindly provided by Dr.  Suresh Su- 
bmmani. Plasmid pSV2CAT,  described by Gorman et al. (1982)  was ob- 
tained from American Type Culture Collection (No. 37155). 
Analysis of  RNA 
Polyadenylated RNA was isolated by oligo(dT) chromatography from cell 
lysates (Schwab et al., 1983). 4-8 ~g aliquots of RNA were electrophoresed 
in 1.2% formaldehyde-agarose gels, transferred to Biodyne nylon filters in 
20  x  SSC and hybridized with nick-translated probes as described earlier 
(Sistonen et al.,  1987). 
Assay of 2-Deoxyglucose (DOG) Uptake 
1-2  ×  105 cells were grown in DME supplemented with  10%  FCS for 
24-48 h after which the cells were kept in 1% FCS for 48 h before the analy- 
sis of 2-DOG uptake according to Flier et al. (1987).  The cells were washed 
three  times  with  PBS  and  then  incubated  in  glucose-free DME  sup- 
plemented with 0.1% BSA and 100 nM 2-DOG for 5 rain at 37°C. 0.5/~Ci 
[3H]2-DOG (17 Ci/mmol) was added and the uptake was interrupted 5 min 
later by the addition of ice-cold PBS containing 0.3 mM phloretin. The cells 
were lysed in 0.1 M NaOH and neutralized with 0.1 M HCI before measure- 
ment of radioactivity by liquid scintillation counting. The 2-DOG uptake 
was related to the total protein content of the cell lysates, which was mea- 
sured with a  protein assay kit  (Bio-Rad Laboratories, Cambridge, MA) 
using BSA as a standard. 
Measurement of  ODC Activity 
About 2  x  l05 cells were seeded and grown in DME containing 10% FCS 
for 48 h before the transfer of the cells into the low-serum medium (0.5% 
FCS). After a further 48 h incubation, EGF or FCS was added to a final 
concentration of 5 nM or 10%, respectively. At the times indicated (0, 2, 
5, 9,  and 24 h), the cells were harvested by scraping and assayed for or- 
nithine decarboxylase (ODC), activity essentially as described earlier (Sis- 
tonen et al.,  1987). 
Metabolic Labeling and Immunoprecipitation 
For immunoprecipitation of neu and EGF-R proteins, rabbit antisera (Leh- 
v~islaiho et aL, 1989), and mouse monoclonal antibodies against the EGF-R 
extracellular domain (RPN.513, Amersham Corp.) were used, respectively. 
The cells were metabolically labeled for 14-16 h with [35S]methionine (100 
ttCi/ml). Autophosphorylation of the EGF-R/neu receptor was analyzed af- 
ter treatment of the metabolically labeled cells with 25 nM EGF for 2 min 
at room temperature after which the cell lysates were immunoprecipitated 
with affinity-purified antiphosphotyrosine antibodies (kindly provided by 
Dr. H. Fujio, Osaka University, Osaka, Japan; Seki et al., 1983), For immu- 
noprecipitation, the cells were lysed in 0.1% SDS, 0.5 % Triton X-100, 0.5 % 
sodium desoxycholate, 20 mM Tris-HCI, pH 7.5, and sonicated for l  min 
at 300 W on ice. The lysates were centrifuged for 30 min at  10,000 rpm 
at +4°C in a HB-4 rotor in a centrifuge (Sorvall, Newtown, CT), and the 
supernatant was divided in 1 ml aliquots into which '~l #l of antibody was 
added and allowed to bind at 4°C for 1 h. For blocking experiments, 2 ~l 
of antibody was preincubated with 2 #g of bacterial neu protein for 20 h. 
About 30 #l of a 50% vol/vol solution of protein A-sepharose (Pharmacia 
Fine Chemicals) was added to the antibody-containing lysates and the tubes 
were mixed gently for 1 h at 4°C. For immunoprecipitation of the EGF-R 
with mouse monoclonal antibodies, rabbit anti-mouse immunoglobulin- 
coated, washed protein A-Sepharose  particles were used. The immune com- 
plexes were washed five times with the immunoprecipitation buffer,  twice 
with PBS, and once with 20 mM Tris-HCl, pH 7.0, dissolved in the dec- 
trophoresis sample buffer containing 2 % SDS, 5 %/3-mercaptoethanol, l0 % 
glycerol, and 50 mM Tris-HCI (pH 6.8),  and boiled for 5 min. 
For detection of the jun and fos proteins, the cells were serum-starved 
in 0.5% FCS for 24 h before either EGF (3 nM) or dialyzed FCS (20%) 
was added to the methionine-free  medium in which the cells were incubated 
for 30 min before methionine labeling (250 tzCi/ml) for 45 min at 37°C. Im- 
munoprecipitation ofthejun protein was carried out using cell lysates preab- 
sorbed with normal rabbit serum and the rabbit polyclonal antisera PEP-I 
and PEP-2 (1:1) produced against synthetic v-jun peptides (kindly provided 
by Dr. Peter K. Vogt; Bohmann et al., 1987).  The sheep anti-c-fos peptide 
antibodies were from Cambridge Research Biochemicals Ltd. (Cambridge, 
UK) (DCP 821). The neu and EGF-R proteins were analyzed in a  7.5% 
SDS-PAGE andjun andros proteins in a  10% SDS-PAGE according to the 
method of Laemmli (1970).  After electrophoresis, the gels were fixed in 
10% acetic acid, impregnated with Amplify (Amersham Corp.), dried onto 
filter paper, and fluorographed (X-Omat R film Eastman Kodak Co., Roch- 
ester, NY). 
The Journal  of Cell Biology,  Volume 109, 1989  1912 Figure 1. Immunoprecipitation (A) and EGF-induced tyrosine kinase activity (B) of the EGF-R, neu and chimeric EGF-R/neu growth factor 
receptors.  A,  The cells  were  labeled with  [35S]methionine overnight and cell lysates were  immunoprecipitated with rabbit antibodies 
against the carboxyl terminal domain of the rat neu receptor expressed in E. coli (Lehv/islaiho et al.,  1989) or with monoclonal anti-EGF-R 
antibodies as detailed in Materials and Methods. Shown is an autofluorogram of SDS-PAGE analysis of anti-neu-precipitates  from the NN, 
NEN37,  N6, and NT12 cells as well as anti-EGF-R-precipitates from the C125 cells. Note that the neu oncogene-transformed NT12 cells 
express smaller amounts of receptor polypeptides than the other receptor transfectants. B, After metabolic labeling overnight, the cells 
were stimulated with 25 nM EGF (for 2 min) or with buffer (0) and lysates were precipitated with anti-neu and antiphosphotyrosine antibod- 
ies,  as shown. 
Assay for CAT Activity 
The cells were seeded at 'x,4 x  105 cells/100 mm plate and grown in medi- 
um containing 10%  FCS for 24 h,  after which they  were  changed into 
medium supplemented with 0.5 % FCS and incubated for a further 20 h. The 
cells were  then transfected  in low-serum  medium with 20 #g of plasmid 
DNA using the calcium phosphate precipitation  method. Incubation with 
the DNA-precipitate  was for 16 h followed by a  1 min rinse in serum-free 
medium containing 20% glycerol.  24 h later, EGF was added at a final con- 
centration of 10 nM, and after 8 h the cells were harvested and the cell ex- 
tracts were prepared by freezing  and thawing the cells in 100 p,I of 0.1 M 
potassium phosphate (pH 7.8),  1 mM DTT. 
The CAT activity was measured essentially  as described by Gorman et 
al. (1982). 60 ~l of the cell extract was incubated at 37°C in a final volume 
of 180/zl together with 0.5 #Ci of [14C]-chloramphenicol.  After 30 min, 
the reaction was stopped and the chloramphenicol was extracted with 1 ml 
of cold ethyl  acetate.  14C-labeled chioramphenicol was  separated  from 
acetylated forms by developing the silica gel thin-layer plates in chloroform- 
methanol (95:5; ascending). After autoradiography  of the separatexi ace- 
tylated chloramphenicol forms,  the  radioactive spots  were cut out and 
counted. The CAT activity was calculaled by determining the percentage of 
acetylated chloramphenicol per mg protein assayed with a Protein Assay Kit 
(Bio-Rad  Laboratories). 
Luciferase Assay 
All CAT constructs were cotransfected  in ratio of 1:5 with the pRSVL plas- 
mid. Luciferase  activity of the cell extracts was analyzed essentially  as de- 
scribed by de Wet et al. (1987). 50 ~tl of 40 mM ATP and 5/~1 of 20 mM 
luciferin were added in 370/~l of 25 mM glycylglycine (pH 7.8) and 15 mM 
MgSO4 containing 20 ~1 of the cell extract.  The peak light emission was 
recorded with a luminometer (1250; LKB Instruments, BioOrbit, Finland). 
Results 
Autophosphorylation  of the EGF-R/neu Receptor upon 
EGF Stimulation 
For the studies on the effects of neu tyrosine kinase activa- 
tion,  we  used mouse NIH  3T3  cell clones expressing an 
EGF-R/neu hybrid receptor  protein on their surface (Leh~s- 
laiho et al.,  1989). Fig.  1 A shows immunoprecipitation of 
the  metabolically labeled  chimeric receptor from serum- 
starved cells of the clone NEN37 expressing the chimeric 
receptor and a comparison with receptor immunoprecipita- 
tion from neomycin-resistant control cells (NN),  cells ex- 
pressing the EGF receptor (C125),  the neu proto-oncogene 
(N6) or oncogene (NT12).  Fig.  1 B  shows that in NENT/ 
cells the EGF-R/neu chimeric protein was phosphorylated in 
tyrosine in 2 min after the addition of EGF, similarly to the 
clones described earlier (Lehv~slaiho et al.,  1989),  while 
treatment of N6 or NT12 cells had no effect on neu protein 
phosphorylation (Fig.  1 B and data not shown). The EGF-R 
of the C125 cells was also autophosphorylated after EGF- 
stimulation. 
The mRNAs of  jun Transcription Factors and the 
Glucose Transporter Are Induced in Response to EGF 
Stimulation of the Chimeric EGF-R/neu Receptor 
We wanted to test whether the neu tyrosine kinase was capa- 
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mRNAs by EGF-treatment  of cells expressing the chi- 
meric EGF-R/neu proto-oncogene.  The N6  and  NTI2 
cells expressing the neu proto-oncogene and oncogene, 
respectively, and the NEN37 cells expressing the EGF- 
R/neu construct were treated with 5 nM EGF for the indi- 
cated periods  of time,  lysed, and analyzed in Northern 
hybridization with the c-jun,  junB, GT, and ODC cDNA 
probes,  and as a control,  with the GAPDH probe. The 
sizes of the mRNAs are shown on the right in kilobases. 
ble of delivering a signal for the growth activation of quies- 
cent cells. To study this response,  we analyzed the expres- 
sion of genes typically activated during the G0-Gt and GrS 
phases of the cell cycle. The c-jun, junB, and c-fos genes be- 
long to the  group of genes forming the  protein  synthesis- 
independent "immediate early" genomic response to a vari- 
ety  of  cellular  growth  signals  (Almendral  et  al.,  1988; 
Greenberg and Ziff, 1984; Lamph et al., 1988; Lau and Na- 
thans,  1987;  Ryder and Nathans,  1988;  Ryder et al.,  1988; 
Ryseck et al.,  1988).  The glucose transporter (GT) mRNA 
is also induced by growth factors and this induction cannot 
be prevented by protein synthesis inhibitors  (Hiraki et al., 
1988;  Rollins et al.,  1988). 
Polyadenylated RNA was isolated at various times after 
EGF stimulation from the NEN37 cells and hybridized with 
the c-jun, junB, and GT probes. The results are seen in the 
upper two panels of Fig. 2. The c-jun andjunB mRNAs were 
increased about four- and sevenfold after 0.5 h of EGF treat- 
ment, and 1.5-2-fold at 2 h. The GT mRNA was about three- 
and fivefold enhanced at 0.5 h and 2 h of treatment, respec- 
tively. In contrast,  no increase of either jun mRNA or GT 
mRNA was obtained in N6 cells expressing the neu proto- 
oncogene. However, in NT12 cells the GT mRNA levels, but 
notjun mRNA, were constitutively high regardless of EGF 
treatment of the cells. 
Induction of  Ornithine Decarboxylase mRNA 
The N6 and NT12 cells also contained constitutively low and 
high amounts ofODC mRNA, respectively (Fig. 2, GAPDH). 
An EGF-induced increase of ODC mRNA was seen only in 
the NEN37 cells.  The NEN37 cells had somewhat variable 
uninduced levels of ODC mRNA (depending on the extent 
of starvation) and showed an about sixfold induction at 2 h 
(compare Figs.  2  and 3).  Examination of the Northern hy- 
bridization results of Fig. 3 shows that while the expression 
Figure 3. Time course ofjunB and ODC 
mRNA  induction  in  the  EGF-treated 
NN and NENI6 cells. The preparation 
of RNA samples and their analysis with 
thejunB and ODC probes was as shown 
in Fig. 2. About 8 #g of poly(A) ÷ RNA 
was loaded per lane. Note that GAPDH 
mRNA is enhanced beginning 4 h after 
the addition of EGE 
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mide on junB, GT, and ODC 
mRNA  expression  in  the 
NENT/cells. Growth-arrested 
NEN37 cells were treated with 
EGF (5 nM; black columns), 
cycloheximide (10 #g/ml; grey 
columns) or  with  both  EGF 
and CHX (white columns). At 
the  indicated  times  poly(A) + 
RNA  was  isolated  and  ana- 
lyzed by Northern  blotting and hybridization  with the junB, GT, 
and ODC probes. The autoradiographic signals were quantitated by 
scanning densitometry and the results expressed as fold of  induction 
over control. 
ofjunB was maximal during the first half an hour of EGF 
treatment and had declined at 6 h back to baseline levels, the 
expression of ODC mRNA was first enhanced at 2  h of EGF 
stimulation and reached a maximum (a sixfold increase) at 
4 h of EGF treatment in the NENI6 cells (expressing ,04  x 
l& chimeric receptors/cell),  returning thereafter slowly to 
preinduction levels. In contrast,  only about a twofold tran- 
sient induction ofjunB and ODC mRNAs was seen in the 
neomycin-resistant  NIH  3T3  cell  clone  NN  treated  with 
EGE Also the GAPDH mRNA was slightly enhanced begin- 
ning 4  h  after EGF treatment. 
The Induction of  Early mRNAs by the neu ~rosine 
Kinase Is Independent of  Protein Synthesis 
To determine whether the  induction  of the junB,  GT, and 
ODC mRNAs required new protein synthesis we analyzed 
the effect of cycloheximide (CHX) on the mRNA levels in- 
duced  by  EGF.  Serum-starved NENT/  cells  were  treated 
with EGF with or without CHX for 0.5, 2, and 4  h. Control 
experiments were performed with CHX alone. Fig. 4 shows 
the relative amounts ofjunB, GT, and ODC mRNAs in the 
cells quantitated by scanning densitometry. CHX slightly in- 
creased  the  maximal  EGF-induced  GT  levels  at  2  h  and 
caused a  more striking accumulation of the GT mRNA at 
4  h, when the mRNA content was returning to basal levels 
in ceils not treated with CHX. CHX also increased the in- 
duction of ODC mRNA levels from 2.5- to 4.5-fold at 2  h 
and  from 6- to 20-fold at 4  h,  respectively. EGF also in- 
creasedjunB mRNA in the presence of CHX, although CHX 
did not further enhance the EGF-induced response at 0.5 h. 
However, CHX prevented the downregulation  of the junB 
mRNA response at later time points (data not shown). 
Increased Synthesis of the Jun and Fos 
Transcription Factors 
The induction of thejun andfos oncogene-encoded polypep- 
tides was analyzed by labeling the EGF-stimulated ceils, and 
for comparison, serum-stimulated cells with 3sS-methionine 
for 45 rain beginning 30 rain after the addition of the growth 
factors and immunoprecipitating cell lysates with the jun- 
and los-specific  peptide antisera.  As expected on the basis 
of the  results of mRNA analysis of the neu  oncogene-ex- 
pressing cells,  the biosynthesis of the jun protein was not 
significantly elevated in the neu oncogene-expressing NT11 
cells and only slightly  increased by EGF in the NIH 3T3 
cells,  NTI1 cells or N6 cells expressing the neu proto-on- 
cogene (Fig. 5). In contrast, EGF increased the jun protein 
levels of NENT/cells more than 10-fold, which was of the 
same order as the stimulation obtained by serum in several 
experiments.  Similar results were obtained for the expres- 
sion of thefos protein, but thefos immunoprecipitates also 
contained several other polypeptides, at least one of which 
comigrated with thejun polypeptides (Fig. 5 B). In conclu- 
sion, the cells expressing the chimeric receptor are capable 
of inducing the fos/jun protein complex, which is essential 
for the  subsequent  activation of genes containing  the  en- 
hancer consensus sequence forjun/AP-1/PEA-1 binding (Chiu 
et al.,  1988). 
Activated neu l~rosine Kinase Is Associated with 
Increased AP-I/PEA-I Activity 
If  the immunoprecipitatedfos/jun  complex is functional after 
EGF stimulation, promoters containing the consensus AP- 
1/PEA-1  binding  sequence  should be activated in the cells 
Figure 5. Immunoprecipitation  ofjun and fos proteins from EGF-treated cells.  Serum-starved NEN37 cells,  and as controls,  NIH 3T3, 
and NTll cells were treated with 10 nM EGF or 20% dialyzed FCS, labeled with [3~S]methionine and immunoprecipitated with the rabbit 
anti-jun or anti-fos peptide antibodies. Note that FCS induces bothjun andfos proteins in the NIH 3T3 and NTI1 cells, while EGF does 
not. In contrast,  EGF induces thejun and fos proteins more strongly than FCS in the NENT/cells. Note also that several polypeptides 
are coprecipitated with the anti-fos antibodies and that one of the coprecipitated polypeptides comigrates with thejun protein. The black 
spots in the second lane of the right panel are artefacts of autoradiographic  exposure. 
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duced by activated neu. Serum-starved NEN37 and NT8 cells were 
transfected with the SV2CAT (SC), BLCAT2,  or with the 5xTREtk- 
CAT constructs together with pRSVL as described in the Materials 
and Methods. After 40 h the cells were stimulated with 10 nM EGF 
or 100nM TPA for 8 h and then analyzed for CAT activity. CM and 
AC indicate unacetylated and acetylated forms of the 14C-labeled 
chloramphenicol, respectively. 
(Chiu et al.,  1988; Rauscher III et al.,  1988). We examined 
the ability of  the neu tyrosine kinase to induce transactivation 
of a  recombinant CAT expression vector having an AP-1/ 
PEA-l-dependent 12-O-tetradecanoyl-phorbol4  3-acetate- 
responsive element (TRE) by using indicator plasmid trans- 
fection into the NEN37 cells. Serum-starved cells were trans- 
fected either with the plasmid p5xTREtkCAT containing a 
fivefold TRE dement linked upstream of the thymidine ki- 
nase promoter and the CAT gene.  Alternatively, a  similar 
plasmid  pBLCAT2  lacking  the  TRE  sequences  was  used 
(Angel  et al.,  1987).  The luciferase plasmid pRSVL was 
cotransfected with the reporter recombinants pBLCAT2 and 
p5xTREtkCAT as an internal control for variations in trans- 
fection efficiency of different cell clones. 40 h after transfec- 
tion part of the transfected cells were treated with  10 nM 
EGF or 100 nM TPA for 8 h, after which cell extracts were 
prepared and assayed for luciferase and CAT activities (Gor- 
man et al.,  1982; de Wet et al.,  1987). Similar levels of lu- 
ciferase activity were obtained from the NEN and NT cells 
transfected simultaneously with the same DNA precipitate, 
suggesting that the transfection efficiency did not differ sig- 
nificantly between these cells (data not shown).  However, 
comparisons of CAT activity between the cells were normal- 
ized to luciferase activities, where small variation occurred. 
An *2.5-fold increase in CAT activity was obtained in NEN37 
cells stimulated either with EGF or TPA, when compared 
with the CAT activity in untreated cells from the same trans- 
fections (Fig. 6). Interestingly, both of  the two neu oncogene- 
expressing cells tested (NT8 and NT 12) showed a high basal 
level of AP-1/PEA-1 activity (about 4-fold enhanced), which 
was insensitive to both EGF and TPA stimulation (Fig. 6, and 
data not shown). 
Stimulation of Glucose Transport 
Stimulation of glucose transport provides a sensitive way of 
analyzing growth  factor responses in  cells (Martin et al., 
1971). We tested the activity of the glucose transporter by 
measuring  the  rate of uptake of 2-DOG  into EGF-treated 
cells. The cells were growth-arrested by placing the nearly 
confluent cultures in medium supplemented with  1% FCS 
for 48 h, after which the cells were treated either with EGF 
or dialyzed FCS. After a 2 h exposure to EGF, the NEN37 
cells expressing the EGF-R/neu receptors showed markedly 
increased rates of 2-DOG uptake (two- to threefold increase 
during the first 8 h), whereas the EGF-treated N6 and NT11 
cells displayed very little change of 2-DOG transport through- 
out the experiment (Fig. 7). In the C125 cells, which express 
similar levels of EGF receptors, the 2-DOG uptake rate was 
linearly increased  for up to threefold after 8  h  treatment 
with EGF or serum.  The uptake was stimulated by serum 
also in the other cell clones, although the induction was only 
about twofold in neu-oncogene expressing NT11 cells, which 
showed a constitutively accelerated rate of glucose transport 
(Fig. 7, legend), characteristic for oncogenically transformed 
cells (Flier et al.,  1987). 
ODC Is Stimulated by the Activated neu 
Tyrosine Kinase 
Measurement of ODC activity from cell lysates after various 
periods of EGF stimulation showed that while the uninduced 
levels of ODC  activity were similarly reduced in  starved 
NENT/cells expressing the ECF-R/neu chimera and in con- 
trol cells, EGF increased ODC activity considerably only in 
the EGF-R/neu receptor-expressing cells (Fig. 8). However, 
a very small and transient increase of the ODC activity was 
also observed in the EGF-treated control cells. This increase 
is not apparent in Fig. 8 because of the scale of the ODC ac- 
tivity. In NEN37 cells that were starved for serum for 2 d the 
activity of ODC was  ,,o60-fold increased (from 0.09 to 5.4 
nmol/mg protein/h) 2  h after EGF stimulation and further 
stimulated 70-fold (from 0.1  to 6.8 nmol/mg protein/h) and 
300-fold (from 0.09 to 26.4 nmol/mg protein/h) at 9 h  and 
24 h,  respectively. When the serum-starvation of cells was 
reduced to 24 h, the EGF-induction of  ODC followed a much 
more rapid kinetics, with the maximal activity level reached 
! 
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Figure 7. Effects of EGF and serum on 2-DOG uptake. About 80% 
confluent cultures of N6, NTll, NEN37, and C125 cells were in- 
cubated in DME supplemented with 1% FCS for48 h. EGF or dia- 
lyzed FCS was added to final concentrations of 10 nM or 10%, 
respectively. After the indicated times the uptake of 2-DOG was 
measured as described in Materials and Methods. Each value (open 
circles  for EGF treatment,  closed  circles  for serum  treatment) 
represents the mean value of at least two separate experiments. At 
the time point zero the following rates of 2-DOG uptake were ob- 
tained: N6 cells, 54 cpm/5 min/#g prot.; NTll cells,  158 cpm/5 
min/#g prot.; NEN37 cells, 35 cpm/5 min/#g prot. 
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Figure 8.  Kinetics of ODC activity in serum-starved ceils treated 
either with 5 nM EGF or 10% serum. Open and closed circles show 
the  ODC  activities of the  untreated and  EGF-treated NN,  N6, 
NT12, and NEN37 cells, respectively. Serum-induced ODC activi- 
ties of the NN cells and the NEN37 cells are indicated with closed 
squares. 
as early as in 2  h  (data not shown).  Similar results were 
obtained with the other cell clones.  (NEN7,  NEN16,  and 
NEN49) expressing the chimeric receptor (data not shown). 
It is also notable that the increase in ODC activity upon EGF 
treatment of NENT/ cells was approximately of the same 
magnitude  as  was  obtained  with  serum  stimulation.  The 
ODC activity obtained in NN cells after serum stimulation 
was higher than that obtained with EGF but still much below 
the induced ODC activities in NEN37 cells. Thus, the maxi- 
mal  ODC  activity measured  in  EGF-stimulated  chimeric 
EGF-R/neu cells was several 100-fold the activity measured 
from the EGF-stimulated neomycin-resistant control cells or 
from the N6 cells expressing the proto-oncogene. In con- 
trast, the NT12 cells expressing the neu oncogene had "~500- 
fold elevated, EGF-independent ODC activity (Fig.  8). 
Discussion 
Our results show that the activated neu tyrosine kinase in- 
duces changes of transcriptional, nutrient transport and en- 
zymatic activities typical for cell growth activation and cell 
cycle progression of growth factor-stimulated cells. These 
effects mimic those induced by EGF in EGF-receptor ex- 
pressing cells (DiPasquale et al., 1978; Quantin and Breath- 
nach, 1988; Hiraki et al.,  1988). One of the earliest changes 
in gene expression induced by the activation of the neu tyro- 
sine kinase is the induction of the mRNA and protein for the 
jun transcription factors, followed by an increase in the ex- 
pression of the GT and ODC mRNAs. Interestingly, all three 
mRNAs were induced in the presence of  the protein synthesis 
inhibitor CHX, indicating that these genes are stimulated by 
preexisting factors in the responding cells.  Possibly,  such 
factors become modified by posttranslational mechanisms, 
such  as  protein  phosphorylation and  become capable  of 
stimulating the transcription of the set of immediate early 
and early responding genes. 
Our immunoprecipitation results indicated that cells of the 
NEN37 clone expressing the chimeric EGF-R/neu protein at 
~4  ×  1@ receptors/cell as well as cells of the clone C125 
expressing the EGF-R at similar levels reacted to EGF stimu- 
lation by a rapid tyrosine phosphorylation of the receptors. 
In contrast, EGF had no effect on the antiphosphotyrosine 
immunoprecipitation of neu proteins from cells of the N6 or 
NT  12 clones expressing the neu proto-oncogene and on- 
cogene, respectively. These results establish that the cells 
clones used in this study express the EGF-R/neu tyrosine 
kinase and EGF-R kinase activities that are controlled by 
ligand binding and that the neu proto-oncogene and onco- 
gene-encoded kinases are not affected by EGF in the control 
cell clones. 
In  NIH  3T3  ceils  expressing  the  chimeric  EGF-R/neu 
receptor the jun transcription factor mRNAs are enhanced 
within 30 min after addition of EGE These genes, junB and 
c-jun encode protein components of the transcription factor 
AP-1/PEA-1  (see  Curran  and  Franza,  1988).  The  EGF- 
treated cells contain the typical fos/jun transcription factor 
complex as shown by metabolic labeling and inununoprecip- 
itation •1  h after stimulation. This complex can also be seen 
at similar elevated levels in serum-stimulated NEN cells and 
control cells, but it is not precipitated from the EGF-treated 
control cells,  including  cells  transformed by the  neu  on- 
cogene. 
Thefos/jun complex has been shown to bind tightly to the 
TRE enhancer DNA elements and to activate transcription 
of promoters  under  their  influence  (Angel  et  al.,  1987, 
1988a; Chiu et al,, 1988). Interestingly, thefos/jun complex 
has also autostimulatory and inhibitory properties on the ex- 
pression of the c-fos and c-jun genes themselves (Angel et 
al.,  1988b; Sassone-Corsi et al.,  1988). We show evidence 
for an increased AP-1/PEA-1 transcription factor activity in 
the EGF-treated cells expressing the chimeric receptor by 
use of a recombinant 5xTRE-CAT vector and transient ex- 
pression assays. The effect of EGF measured at 8 h of stimu- 
lation was comparable to the degree of induction by TPA and 
to the activity present in unstimulated neu oncogene-express- 
ing cells. It is possible that the increase in the amount of the 
fos/jun complex, induced by the ligand activation of the neu 
tyrosine kinase, is capable of activating the subsequent set 
of genes, whose expression is dependent on the synthesis of 
novel proteins and can therefore be classified as "early" growth 
factor-induced genes. However, the reason for the high con- 
stitutive activity of a TRE element in transformed cells re- 
mains unknown. Our experiments with the ras and neu on- 
cogenes suggest that elevated  jun and fos mRNA and protein 
expression may not be responsible for this difference (Sisto- 
nen et al., 1989; our present study). Possibly, thefos protein 
might be  modified by constitutive posttranslational  phos- 
phorylation subsequent to the mutational activation of the 
neu tyrosine kinase and the modified fos/jun complex then 
could maintain  several  genomic  responses.  On  the  other 
hand, we have not yet analyzed the possibility that these pro- 
teins would be more stable in the transformed cells. 
Since an accelerated rate of glucose transport is among the 
most characteristic biochemical markers of growth stimula- 
tion and the transformed phenotype, we decided to use the 
analysis of the GT gene expression to study the pattern and 
kinetics of gene activation in our EGF dependent growth and 
transformation model system, cDNAs encoding the human 
hepatoma (Mueckler et al.,  1985) and the rat brain (Birn- 
baum et al.,  1986) GT have been used to demonstrate that 
elevated levels of GT mRNA are associated with an acceler- 
ated rate of glucose transport in oncogenically transformed 
cells (Birnbaum et al., 1987). In the case of cells transformed 
with v-src or activated c-ras oncogenes, it was suggested that 
the  signal  transduction  mechanisms  activated by  the  on- 
cogene would be associated with the elevated GT mRNA ex- 
pression  (Flier  et  al.,  1987).  In  accordance  with  these 
results,  the increased rate of glucose transport in the neu 
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elevated GT mRNA levels. 
Recently, it has also been shown that serum and the puri- 
fied growth factors EGF, PDGF and FGF regulate the glu- 
cose transport system at a transcriptional level (Hiraki et al., 
1988; Rollins et al., 1988). The GT mRNA induction in the 
NEN cells expressing the EGF-R/neu receptor was indepen- 
dent of protein synthesis, as has been found using other cells 
and EGF and PDGF receptor-ligand systems (Hiraki et al., 
1988; Rollins et al., 1988). The time course of EGF-induced 
GT mRNA increase correlates with the actual increase of 
glucose transport measured by the uptake of 2-DOG,  al- 
though the mRNA levels  were already declining at 4 h of 
treatment, when the 2-DOG transport rate was still rising. 
The maximal enhancement of the GT mRNA was about six- 
fold, whereas the maximal transport rate was threefold over 
unstimulated values.  This parallels the results of Rollins et 
al.  (1988)  and supports the hypothesis on the existence of 
translational and posttranslational controls of GT expression. 
We have previously shown that in NIH 3T3 cells, where 
expression of the activated c-Ha-ras oncogene is induced 
from the human heat shock promoter 70 the onset of synthe- 
sis of p21 °-"'-ras oncoprotein is rapidly followed by elevated 
mRNA levels of thejunB, c-jun, GT and ODC genes (Sisto- 
nen et al., 1989). Our present results show that the neu tyro- 
sine kinase is also capable of enhancing the expression of 
these mRNAs, with jun mRNA rising first and the GT and 
ODC mRNAs thereafter. It has previously been shown that 
the  mitogenic induction of ODC  mRNA results,  at least 
partly, from increased transcription of the ODC gene (Katz 
and Kahana, 1987). The ODC activity follows these changes, 
but the timing of the peak of ODC activity after EGF stimu- 
lation is dependent on the length of prior cell starvation, the 
dosage of EGF, and the number of receptors on the respond- 
ing cells. It is of interest that the maximal ODC activities 
stimulated by EGF and serum in the NEN37 cells are of simi- 
lar  magnitude and closely correspond  to  the constitutive 
ODC activity of the neu oncogene-transformed cells. Fur- 
ther, the induction of ODC by EGF in the chimeric EGF- 
R/neu expressing cells precedes by several hours their mor- 
phological transformation. All these results are consistent 
with the view that ODC is expressed during the G, period 
of the cell cycle, and that the length of the lag period depends 
on the state of the cells in the G,/Go phase of the cell cycle 
before cell stimulation. Thus, this study further strengthens 
our earlier  suggestions based on the c-Ha-ms oncogene- 
transformed cells (Sistonen et al., 1987; H61ttfi et al., 1988) 
that  a  deregulated  expression  of ODC  is  intimately as- 
sociated with cell transformation and that a high constitutive 
activity of ODC is typical for stably transformed cells. 
The neu  oncogene is activated by a  point mutation ex- 
changing glutamic acid for valine in the transmembrane do- 
main of the receptor (Bargmann et al., 1986b).  However, it 
is not known how the neu oncoprotein transforms cells. En- 
hanced tyrosine kinase activity and an increased phospho- 
tyrosine content have been reported for the neu oncoprotein 
in rat cells (Bargmann and Weinherg, 1988a,b; Stern et al., 
1986;  1988). The half-life of the oncoprotein is also shorter 
than the half-life of the proto-oncogene-encoded neu protein 
(Stern et al.,  1988),  suggesting that the oncoprotein under- 
goes a more rapid rate of internalization and is also targeted 
to enhanced degradation in lysosomes as proposed for the 
EGF-R (Schlessinger,  1988). This view is consistent with the 
recent model for the effects of the activating point mutation 
of the neu oncoprotein, which may greatly increase the rate 
of receptor dimerization, normally occurring only after li- 
gand stimulation of the neu proto-oncogene-encodcd recep- 
tor (Sternberg and Gullick, 1989). Our chimeric EGF-R/neu 
receptor allows at least a tentative model for comparison of 
the biochemistry and genomic effects of the ligand- and on- 
cogenically activated neu receptors. The present study indi- 
cates that both types of receptor activation lead to similar 
biochemical changes  typical  for growth  factor-stimulated 
and transformed cells. Interesting differences also exist, as 
is shown here for the activation of the fos/jun transcription 
factor complex in the presence and absence of an increase 
of the corresponding protein components in ligand-stimulated 
and constitutively neu-transformed cells. The further analy- 
sis of such differences will undoubtedly shed light on the 
pathways of growth factor signal transduction and their de- 
rangements in transformed cells. 
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